Vanda Pharmaceuticals Netherlands

Iloperidone (FANAPTUM) is an oral small-molecule antipsychotic approved for the treatment of schizophrenia. Developed and marketed by Vanda Pharmaceuticals Netherlands B.V., the drug represents a therapeutic option within the nervous system (N05) class. The program, identified by internal code VP-VYV-683-1005, has achieved regulatory approval in both the United States and European Union, with U.S. approval granted under NDA022192 and multiple generic applications subsequently authorized. European authorization was granted on 15 January 2018 and 14 December 2012 under EMEA product numbers EMEA/H/C/002371, EMEA/H/C/004149, and EMEA/H/C/006561.

Iloperidone is administered orally and competes within a crowded antipsychotic market that includes established agents such as olanzapine, risperidone, aripiprazole, and lurasidone. The program maintains active status as of the latest milestone dated 12 January 2026. Five clinical trials have been registered (NCT00254202, NCT01291511, NCT04712734, NCT05648591, NCT06961968), though specific trial designs, endpoints, and results are not disclosed in available data. The mechanism of action and specific molecular target remain undisclosed. Vanda Pharmaceuticals operates without a disclosed development partner for this indication.

The regulatory landscape reflects mature market positioning, with generic competition authorized in the United States through multiple abbreviated new drug applications (ANDA206890, ANDA207098, ANDA207231, ANDA207409). The European regulatory pathway has involved multiple marketing authorization holders. Peak sales projections, consensus positioning, and expected next clinical milestones have not been disclosed.

Schizophrenia remains a significant unmet medical need affecting approximately 1% of the global population, characterized by positive symptoms (hallucinations, delusions), negative symptoms (social withdrawal, reduced motivation), and cognitive dysfunction. Antipsychotic medications form the cornerstone of treatment, yet efficacy and tolerability vary substantially across individual patients, driving continued clinical demand for therapeutic alternatives.

Iloperidone's market relevance derives from its positioning as an oral atypical antipsychotic within a competitive landscape dominated by first-generation and established second-generation agents. The drug competes directly against olanzapine (APO-OLANZAPINE ODT), risperidone (APO-RISPERIDONE), aripiprazole (ABILIFY), lurasidone (APO-LURASIDONE), and brexpiprazole (REXULTI), among others. Commercial significance is tempered by the presence of multiple generic competitors in the U.S. market, which has compressed pricing and market share potential.

The patient population encompasses individuals with acute and chronic schizophrenia requiring oral antipsychotic therapy. Differentiation from competitors typically centers on efficacy-tolerability profiles, dosing convenience, and individual patient response patterns. Vanda Pharmaceuticals' portfolio strategy includes concurrent development of other CNS agents (HETLIOZ for circadian rhythm sleep-wake disorders), suggesting a focused approach to neuropsychiatric indications. The mature regulatory status and generic competition indicate that commercial growth depends on clinical differentiation, formulary positioning, and patient-specific treatment algorithms rather than patent-driven exclusivity.

Drug Class: Atypical antipsychotic (second-generation antipsychotic)

Modality: Small molecule

Route of Administration: Oral

Therapeutic Classification: Nervous system (ATC N05)

Brand Name: FANAPTUM

International Nonproprietary Name (INN): Iloperidone

Mechanism of Action: Not yet disclosed in available regulatory data

Molecular Target: Not yet disclosed in available regulatory data

• Related approved antipsychotics in the competitive set include olanzapine, risperidone, aripiprazole, lurasidone, and brexpiprazole, all of which are oral atypical antipsychotics approved for schizophrenia.
• First approval in the United States occurred under NDA022192; European authorization followed with multiple EMEA product numbers reflecting different formulations or marketing authorization holders.
• Patent status is not yet disclosed.
• Generic competition has been authorized in the U.S. market through multiple abbreviated new drug applications, indicating loss of market exclusivity.

United States (FDA): Iloperidone is approved under NDA022192. Multiple generic manufacturers have received abbreviated new drug applications (ANDA206890, ANDA207098, ANDA207231, ANDA207409) from sponsors including Alembic Pharmaceuticals Ltd, Inventia, Lupin, and Taro, indicating loss of market exclusivity and active generic competition.

European Union (EMA): Iloperidone holds marketing authorization under three EMEA product numbers: EMEA/H/C/002371, EMEA/H/C/004149, and EMEA/H/C/006561. Marketing authorization holders include Vanda Pharmaceuticals Ltd and Vanda Pharmaceuticals Netherlands B.V. Authorization dates are 14 December 2012 and 15 January 2018. Current EU regulatory status is not yet disclosed.

Japan (PMDA): Regulatory status not yet disclosed.

China (NMPA): Regulatory status not yet disclosed.

• Therapeutic class: Nervous system (ATC N05)
• Route of administration: Oral
• Modality: Small-molecule antipsychotic

Strategic Positioning: Iloperidone represents a mature, approved antipsychotic with established regulatory status in the U.S. and EU but limited patent exclusivity. Vanda Pharmaceuticals' maintenance of active development status (as of January 2026) suggests ongoing clinical investigation, though specific objectives and expected milestones are not disclosed. The presence of five registered clinical trials (NCT00254202, NCT01291511, NCT04712734, NCT05648591, NCT06961968) indicates potential label expansion, pharmacokinetic studies, or comparative efficacy investigations, but trial designs and endpoints remain undisclosed.

Competitive Implications: The antipsychotic market is characterized by therapeutic commoditization, with generic competition eroding pricing power and market share. Iloperidone competes against established agents (olanzapine, risperidone, aripiprazole) and newer entrants (lurasidone, brexpiprazole) on efficacy-tolerability profiles and formulary positioning rather than patent-driven exclusivity. Multiple U.S. generic approvals (ANDA206890, ANDA207098, ANDA207231, ANDA207409) confirm market saturation and price compression.

Future Catalysts: Potential catalysts include disclosure of clinical trial results from the five registered studies, label expansion indications (e.g., bipolar disorder, treatment-resistant schizophrenia), new formulation development (e.g., long-acting injectables), or pharmacogenomic data supporting patient selection. Peak sales projections and consensus analyst positioning are not yet disclosed, limiting commercial upside assessment.

• Expected next milestone: Not yet disclosed
• Projected peak sales: Not yet disclosed
• Consensus positioning: Not yet disclosed